Published in Endocrinology on March 01, 1992
Down-regulation of PROS1 gene expression by 17beta-estradiol via estrogen receptor alpha (ERalpha)-Sp1 interaction recruiting receptor-interacting protein 140 and the corepressor-HDAC3 complex. J Biol Chem (2010) 0.98
Protein S is inducible by interleukin 4 in T cells and inhibits lymphoid cell procoagulant activity. Proc Natl Acad Sci U S A (1997) 0.92
Beyond deficiency: potential benefits of increased intakes of vitamin K for bone and vascular health. Eur J Nutr (2004) 0.91
Vitamin K and metabolic bone disease. J Clin Pathol (1998) 0.85
Integrative physiology: defined novel metabolic roles of osteocalcin. J Korean Med Sci (2010) 0.85
Dependence on vitamin K-dependent protein S for eukaryotic cell secretion of the beta-chain of C4b-binding protein. J Biol Chem (2010) 0.78
Annexin-enriched osteoblast-derived vesicles act as an extracellular site of mineral nucleation within developing stem cell cultures. Sci Rep (2017) 0.75
Vitamin D3 and calcium to prevent hip fractures in the elderly women. N Engl J Med (1992) 9.86
European guidance for the diagnosis and management of osteoporosis in postmenopausal women. Osteoporos Int (2008) 5.27
Dietary supplementation in elderly patients with fractured neck of the femur. Lancet (1990) 4.47
Alendronate for the prevention and treatment of glucocorticoid-induced osteoporosis. Glucocorticoid-Induced Osteoporosis Intervention Study Group. N Engl J Med (1998) 4.38
Do we need to change the WHO definition of osteoporosis? Osteoporos Int (2000) 3.35
Serum bone Gla-protein: a specific marker for bone formation in postmenopausal osteoporosis. Lancet (1984) 2.85
Ultrasonographic heel measurements to predict hip fracture in elderly women: the EPIDOS prospective study. Lancet (1996) 2.83
Current use of bisphosphonates in oncology. International Bone and Cancer Study Group. J Clin Oncol (1998) 2.73
Interim report and recommendations of the World Health Organization Task-Force for Osteoporosis. Osteoporos Int (1999) 2.70
Markers of bone resorption predict hip fracture in elderly women: the EPIDOS Prospective Study. J Bone Miner Res (1996) 2.61
Effect of calcium and cholecalciferol treatment for three years on hip fractures in elderly women. BMJ (1994) 2.61
Increased bone turnover in late postmenopausal women is a major determinant of osteoporosis. J Bone Miner Res (1996) 2.59
The collagenolytic activity of cathepsin K is unique among mammalian proteinases. J Biol Chem (1998) 2.48
Comparison of new biochemical markers of bone turnover in late postmenopausal osteoporotic women in response to alendronate treatment. J Clin Endocrinol Metab (1994) 2.39
Effectiveness of bisphosphonates on nonvertebral and hip fractures in the first year of therapy: the risedronate and alendronate (REAL) cohort study. Osteoporos Int (2006) 2.34
Biochemical markers of bone turnover, endogenous hormones and the risk of fractures in postmenopausal women: the OFELY study. J Bone Miner Res (2000) 2.24
The role of collagen in bone strength. Osteoporos Int (2005) 2.19
Cross sectional evaluation of biochemical markers of bone, cartilage, and synovial tissue metabolism in patients with knee osteoarthritis: relations with disease activity and joint damage. Ann Rheum Dis (2001) 2.18
Insights into material and structural basis of bone fragility from diseases associated with fractures: how determinants of the biomechanical properties of bone are compromised by disease. Endocr Rev (2006) 2.08
Undercarboxylated osteocalcin measured with a specific immunoassay predicts hip fracture in elderly women: the EPIDOS Study. J Clin Endocrinol Metab (1997) 2.04
Relationship of early changes in bone resorption to the reduction in fracture risk with risedronate. J Bone Miner Res (2003) 1.96
Molecular basis and clinical use of biochemical markers of bone, cartilage, and synovium in joint diseases. Arthritis Rheum (2000) 1.85
Measurement of bone mineral content of the lumbar spine by dual energy x-ray absorptiometry in normal children: correlations with growth parameters. J Clin Endocrinol Metab (1990) 1.83
Serum undercarboxylated osteocalcin is a marker of the risk of hip fracture: a three year follow-up study. Bone (1996) 1.80
Serum undercarboxylated osteocalcin is a marker of the risk of hip fracture in elderly women. J Clin Invest (1993) 1.78
Exercise before puberty may confer residual benefits in bone density in adulthood: studies in active prepubertal and retired female gymnasts. J Bone Miner Res (1998) 1.77
Ibandronate for the prevention of nonvertebral fractures: a pooled analysis of individual patient data. Osteoporos Int (2008) 1.76
The effect of vitamin D supplementation on vitamin D status and parathyroid function in elderly subjects. J Clin Endocrinol Metab (1988) 1.71
Long-term effects of intravenous pamidronate in fibrous dysplasia of bone. Lancet (1994) 1.71
How hip and whole-body bone mineral density predict hip fracture in elderly women: the EPIDOS Prospective Study. Osteoporos Int (1998) 1.70
Increase in serum bone gamma-carboxyglutamic acid protein with aging in women. Implications for the mechanism of age-related bone loss. J Clin Invest (1983) 1.69
The type I collagen fragments ICTP and CTX reveal distinct enzymatic pathways of bone collagen degradation. J Bone Miner Res (2003) 1.68
Acquired protein S deficiency: correlation with advanced disease in HIV-1-infected patients. J Acquir Immune Defic Syndr (1992) 1.67
Efficacy and tolerability of once-monthly oral ibandronate in postmenopausal osteoporosis: 2 year results from the MOBILE study. Ann Rheum Dis (2005) 1.66
Urinary excretion of pyridinium crosslinks: a new marker of bone resorption in metabolic bone disease. Bone Miner (1990) 1.62
The deleterious effects of low-dose corticosteroids on bone density in patients with polymyalgia rheumatica. Br J Rheumatol (1998) 1.59
Two-year effects of alendronate on bone mineral density and vertebral fracture in patients receiving glucocorticoids: a randomized, double-blind, placebo-controlled extension trial. Arthritis Rheum (2001) 1.58
Glucocorticoid-induced inhibition of osteoblastic bone formation in ewes: a biochemical and histomorphometric study. Osteoporos Int (1993) 1.58
Strontium ranelate: dose-dependent effects in established postmenopausal vertebral osteoporosis--a 2-year randomized placebo controlled trial. J Clin Endocrinol Metab (2002) 1.57
Markers of bone turnover for the management of patients with bone metastases from prostate cancer. Br J Cancer (2000) 1.56
Incidence of limb fracture across Europe: results from the European Prospective Osteoporosis Study (EPOS). Osteoporos Int (2002) 1.56
Independent predictors of all osteoporosis-related fractures in healthy postmenopausal women: the OFELY study. Bone (2003) 1.54
Early detection of bone metastases in a murine model using fluorescent human breast cancer cells: application to the use of the bisphosphonate zoledronic acid in the treatment of osteolytic lesions. J Bone Miner Res (2001) 1.54
Healthy elderly French women living at home have secondary hyperparathyroidism and high bone turnover in winter. EPIDOS Study Group. J Clin Endocrinol Metab (1996) 1.53
Characterization of the platelet membrane glycoprotein abnormalities in Bernard-Soulier syndrome and comparison with normal by surface-labeling techniques and high-resolution two-dimensional gel electrophoresis. J Clin Invest (1982) 1.50
Biochemical markers of bone turnover: potential use in the investigation and management of postmenopausal osteoporosis. Osteoporos Int (2008) 1.50
Alendronate treatment of the postmenopausal osteoporotic woman: effect of multiple dosages on bone mass and bone remodeling. Am J Med (1995) 1.48
Prevention of early postmenopausal bone loss with cyclical etidronate therapy (a double-blind, placebo-controlled study and 1-year follow-up) J Clin Endocrinol Metab (1997) 1.48
Serum and synovial fluid osteocalcin (bone gla protein) levels in joint disease. Br J Rheumatol (1989) 1.48
Bisphosphonates alter trabecular bone collagen cross-linking and isomerization in beagle dog vertebra. Osteoporos Int (2007) 1.47
Long-term effects of intravenous pamidronate in fibrous dysplasia of bone. J Bone Miner Res (1997) 1.42
Apparent pre- and postmenopausal bone loss evaluated by DXA at different skeletal sites in women: the OFELY cohort. J Bone Miner Res (1997) 1.42
Evidence for a dense and intimate innervation of the bone tissue, including glutamate-containing fibers. Bone (1999) 1.41
Which screening strategy using BMD measurements would be most cost effective for hip fracture prevention in elderly women? A decision analysis based on a Markov model. Osteoporos Int (2006) 1.41
Biochemical measurements of bone turnover in children and adolescents. Osteoporos Int (2000) 1.41
Incorporation and distribution of strontium in bone. Bone (2001) 1.40
Systemic but not renal production of prostacyclin is highly reduced in cyclosporin-treated heart transplant recipients. Am J Cardiol (1993) 1.39
Bisphosphonates inhibit prostate and breast carcinoma cell adhesion to unmineralized and mineralized bone extracellular matrices. Cancer Res (1997) 1.39
Diagnosis and management of osteoporosis in postmenopausal women: clinical guidelines. International Committee for Osteoporosis Clinical Guidelines. Clin Ther (1999) 1.35
Assessment of the serum levels of bone alkaline phosphatase with a new immunoradiometric assay in patients with metabolic bone disease. J Clin Endocrinol Metab (1993) 1.34
Assessment of osteoclast number and function: application in the development of new and improved treatment modalities for bone diseases. Osteoporos Int (2006) 1.33
Bioavailable estradiol may be an important determinant of osteoporosis in men: the MINOS study. J Clin Endocrinol Metab (2001) 1.30
Effect of menopause and hormone replacement therapy on the urinary excretion of pyridinium cross-links. J Clin Endocrinol Metab (1991) 1.30
Effectiveness of instant vertebral assessment to detect prevalent vertebral fracture. Osteoporos Int (2006) 1.30
Low serum IGF-1 and occurrence of osteoporotic fractures in postmenopausal women. Lancet (2000) 1.28
Associations of vitamin D status with bone mineral density, bone turnover, bone loss and fracture risk in healthy postmenopausal women. The OFELY study. Bone (2006) 1.27
Effects of oral chondroitin sulfate on the progression of knee osteoarthritis: a pilot study. Osteoarthritis Cartilage (1998) 1.26
The impact of osteoporosis on quality-of-life: the OFELY cohort. Bone (2002) 1.26
A simple and efficient method for platelet isolation from their plasma. Thromb Res (1980) 1.26
Treatment of fibrous dysplasia of bone with intravenous pamidronate: long-term effectiveness and evaluation of predictors of response to treatment. Bone (2004) 1.25
Increased risk of falls and increased bone resorption in elderly men with partial androgen deficiency: the MINOS study. J Clin Endocrinol Metab (2003) 1.23
Glutamate receptors are expressed by bone cells and are involved in bone resorption. Bone (1998) 1.23
Structural determinants of hip fracture in elderly women: re-analysis of the data from the EPIDOS study. Osteoporos Int (2005) 1.22
Pseudomembranous colitis probably due to rifampicin. Lancet (1980) 1.22
Different morphometric and densitometric parameters predict cervical and trochanteric hip fracture: the EPIDOS Study. J Bone Miner Res (1997) 1.22
The differing tempo of growth in bone size, mass, and density in girls is region-specific. J Clin Invest (1999) 1.21
Body composition in appropriate and in small for gestational age infants. Acta Paediatr (1997) 1.21
Six and twelve month changes in bone turnover are related to reduction in vertebral fracture risk during 3 years of raloxifene treatment in postmenopausal osteoporosis. Osteoporos Int (2001) 1.20
Influence of mature adipocytes on osteoblast proliferation in human primary cocultures. Bone (2000) 1.20
Prevalent vertebral deformity predicts incident hip though not distal forearm fracture: results from the European Prospective Osteoporosis Study. Osteoporos Int (2001) 1.20
Markers of bone turnover predict postmenopausal forearm bone loss over 4 years: the OFELY study. J Bone Miner Res (1999) 1.19
Biochemical indices of bone turnover and the assessment of fracture probability. Osteoporos Int (2002) 1.19
Severity of vertebral fracture reflects deterioration of bone microarchitecture. Osteoporos Int (2006) 1.18
Rapid purification and partial characterization of human platelet glycoprotein IIIb. Interaction with thrombospondin and its role in platelet aggregation. J Biol Chem (1989) 1.18
Cross-sectional assessment of age-related bone loss in men: the MINOS study. Bone (2000) 1.17
Expression of thrombospondin (TSP1) and its receptors (CD36 and CD51) in normal, hyperplastic, and neoplastic human breast. Cancer Res (1993) 1.17
Long-term effects of raloxifene on bone mineral density, bone turnover, and serum lipid levels in early postmenopausal women: three-year data from 2 double-blind, randomized, placebo-controlled trials. Arch Intern Med (2000) 1.17
Ultrasound discriminates patients with hip fracture equally well as dual energy X-ray absorptiometry and independently of bone mineral density. J Bone Miner Res (1995) 1.16
Osteoprotegerin serum levels in men: correlation with age, estrogen, and testosterone status. J Clin Endocrinol Metab (2001) 1.16
Collagen Ialpha1 Sp1 polymorphism, bone mass, and bone turnover in healthy French premenopausal women: the OFELY study. J Bone Miner Res (1998) 1.13
Glycoproteins of platelet membranes from Glanzmann's thrombasthenia. A comparison with normal using carbohydrate-specific or protein-specific labelling techniques and high-resolution two-dimensional gel electrophoresis. Eur J Biochem (1981) 1.13
Assessment of bone resorption with a new marker of collagen degradation in patients with metabolic bone disease. J Clin Endocrinol Metab (1994) 1.12
Urinary type II collagen C-telopeptide levels are increased in patients with rapidly destructive hip osteoarthritis. Ann Rheum Dis (2003) 1.12
Expression of Semaphorin-3A and its receptors in endochondral ossification: potential role in skeletal development and innervation. Dev Dyn (2005) 1.11
Increased bone resorption in moderate smokers with low body weight: the Minos study. J Clin Endocrinol Metab (2002) 1.11
Effect of renal function on plasma levels of bone Gla-protein. J Clin Endocrinol Metab (1983) 1.11